Propanc Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PPCB Nasdaq 2836 www.propanc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update - Jan 13th, 2026 6:45 am
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal - Dec 22nd, 2025 5:00 am
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - Dec 4th, 2025 6:45 am
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis - Dec 1st, 2025 6:45 am
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results - Nov 17th, 2025 6:45 am
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office - Sep 17th, 2025 6:45 am
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting - Aug 28th, 2025 4:00 pm
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ - Aug 19th, 2025 6:30 am
BC-Most Active Stocks - Aug 18th, 2025 8:30 am
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering - Aug 14th, 2025 9:00 pm